Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that the first participant has been enrolled in ZUPREME-2, a phase ...

The Phase 2b ZUPREME-2 trial investigates the efficacy and safety of petrelintide in participants with overweight or obesity and type 2 diabetes. The ZUPREME-2 trial is designed to evaluate three ...

COPENHAGEN, April 24 (Reuters) - Danish biotechnology company Zealand Pharma (ZELA.CO), opens new tab said on Thursday it had enrolled the first patient in a mid-stage trial with its weight-loss ...

The management board of Nordecon AS (the "Company”) (registry code 10099962, address Toompuiestee 35, 10149 Tallinn) hereby calls an annual general meeting of shareholders, which shall be held on 21 ...

Parrot Palace will have a diverse array of species for sale, including cockatoos and cockatiels, quaker and Senegal parrots, parakeets, sun conures, macaws and more. “We have access to anything ...

Zealand Pharma (ZLDPF) announces the appointment of Utpal Singh as Chief Scientific Officer. Utpal will join the executive team to lead discovery research and translational sciences at Zealand ...

Roche's move for the asset comes shortly after Zealand started the phase 2b ZUPREME-1 trial of petrelintide in people overweight or obese, and ahead of the ZUPREME-2 study in overweight or obese ...

Press release – No. 6 / 2025 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes The Phase 2b ...

The company said in a statement that completion of enrolment of around 200 participants in its so-called Phase 2b ZUPREME-1 trial is expected in the second half of this year. Zealand in December 2024 ...